The Clinical Core housed at the Karmanos Cancer Institute is intended to be a resource for the program? project as a whole and as a valuable source of biological materials necessary for the completion of the? individual projects. The Clinical Core will be responsible for the collection, storage, and distribution of? mesothelial cells and tissues, and mesothelioma tumors. The functions of the Clinical Core will be to serve? as a resource for mesothelioma tumor tissue both snap frozen and paraffin embedded, and as a resource for? asbestos-exposed pleura, lung, or peritoneum which is either snap frozen or paraffin embedded. The CORE? will also serve as a resource for already established mesothelioma cell lines as well as an ongoing source of? cultured human mesothelial cells from patients at the Karmanos Cancer Institute. New mesothelioma cell? lines will be started prospectively from mesothleioma patients having resection. The Core will be responsible? for the determining the SV40 status on these human mesothelial tissues, mesothelial cells, mesothelioma? tumors and cultured mesothelioma cell lines in order to provide the appropriate reagents to the investigators.? Tissue arrays for immunohistochemical validation of data will be constructed from paraffin embedded tumors? and provided to the individual investigators. The Clinical Core will also coordinate the performance of? asbestos lung content analysis from patients with mesothelioma for correlative data in the individual projects.? It is estimated that 60-80 new mesothelioma cases per year will be seen at the Karmanos Cancer Institute? during the course of the program project, and it is conservatively estimated that 20-30 of these will be? accrued as fresh/frozen specimens. Paraffin embedded tumors will be available from all cases. Tumor? samples will be used in Projects 1 and 3, and cell lines/cultures will be used in projects 2 and 3. By? centralizing these services into a Core, the collection, storage, analysis, and distribution of tissues relevant to? mesothelioma carcinogenesis will be better managed and coordinated for the entire Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA114047-01A1
Application #
7035626
Study Section
Special Emphasis Panel (ZCA1-GRB-S (JI))
Project Start
2005-12-01
Project End
2010-11-30
Budget Start
2005-12-01
Budget End
2007-08-31
Support Year
1
Fiscal Year
2006
Total Cost
$124,661
Indirect Cost
Name
University of Hawaii
Department
Type
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Napolitano, A; Pellegrini, L; Dey, A et al. (2016) Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35:1996-2002
Nasu, Masaki; Emi, Mitsuru; Pastorino, Sandra et al. (2015) High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 10:565-76
Bononi, Angela; Napolitano, Andrea; Pass, Harvey I et al. (2015) Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med 9:633-54
Baumann, Francine; Buck, Brenda J; Metcalf, Rodney V et al. (2015) The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada. J Thorac Oncol 10:731-7
Baumann, Francine; Flores, Erin; Napolitano, Andrea et al. (2015) Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36:76-81
Baumann, Francine; Buck, Brenda J; Metcalf, Rodney V et al. (2015) Reply to ""No Increased Risk for Mesothelioma in Relation to Natural-Occurring Asbestos in Southern Nevada"". J Thorac Oncol 10:e64-5
Deng, Xu-Bin; Xiao, Li; Wu, Yue et al. (2015) Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy. Int J Cancer 137:481-90
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Yang, H; Pellegrini, L; Napolitano, A et al. (2015) Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis 6:e1786
Menges, Craig W; Kadariya, Yuwaraj; Altomare, Deborah et al. (2014) Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res 74:1261-1271

Showing the most recent 10 out of 52 publications